Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non–small-cell lung cancer prospectively stratified by beta-3 tubulin status

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 1990-1996

  Edelman, Martin J ^a   Schneider, Claus Peter ^b   Tsai, Chun Ming ^d   Kim, Heung Tae ^e   Quoix, Elisabeth ^f   Luft, Alexander V ^g   Kaleta, Remigiusz ^h   Mukhopadhyay, Pralay ^h   Trifan, Ovidiu C ^h   Whitaker, Laura ^h   Reck, Martin ^c  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b ZENTRALKLINIK BAD BERKA   (Germany)

^c KRANKENHAUS GROSSHANSDORF   (Germany)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e National Cancer Center   (South Korea)

^f HÔPITAL CIVIL   (France)

^g Leningrad Regional Clinical Hospital   (Russian Federation)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 3 TUBULIN; BETA TUBULIN; CARBOPLATIN; IXABEPILONE; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE; TUBULIN; TUBULIN MODULATOR; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGE; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FATIGUE; FEMALE; FEVER; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LARGE CELL CARCINOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEURALGIA; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SEX DIFFERENCE; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; SUDDEN CARDIAC DEATH; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; AREA UNDER THE CURVE; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPOTHILONES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBULIN; TUBULIN MODULATORS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84880673560     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.3282     Document Type: Article

References (19)

1. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002
2. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase three trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
3. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
4. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
5. Han JY, Lim HS, Shin ES, et al: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non–small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237-2244, 2006
6. Rosell R, Danenberg KD, Alberola V, et al: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318-1325, 2004
7. Sève P, Dumontet C: Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9:168-175, 2008
8. Sève P, Mackey J, Isaac S, et al: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001-2007, 2005
9. Mozzetti S, Ferlini C, Concolino P, et al: Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11:298-305, 2005
10. Paradiso A, Mangia A, Chiriatti A, et al: Bio-markers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 16:iv14-iv19, 2005 (suppl 4)
11. Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333, 1995
12. Lee FY, Borzilleri R, Fairchild CR, et al: BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437, 2001
13. Lee FY, Smykla R, Johnston K, et al: Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 63:201-212, 2009
14. Jordan MA, Miller H, Ni L, et al: The Pat-21 breast cancer model derived from a patient with primary taxol resistance recapitulates the phenotype of its origin, has altered beta-tubulin expression and is sensitive to ixabepilone. J Clin Oncol 47, 2006 (suppl; abstr LB-280)
15. Dumontet C, Jordan MA, Lee FF: Ixabepilone: Targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8:17-25, 2009
16. Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al: Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non–small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 25:3448-3455, 2007
17. Plummer R, Woll P, Fyfe D, et al: A phase I and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies. Clin Cancer Res 14:8288-8294, 2008
18. Sève P, Isaac S, Trédan O, et al: Expression of class III -tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481-5486, 2005
19. Reiman T, Lai R, Veillard AS, et al: Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials. Ann Oncol 23:86-93, 2012